ME Therapeutics Holdings Inc.
METX
CNSX
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.25% | 30.93% | -30.81% | 12.81% | 20.98% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -98.32% | -98.93% | 108.22% | -27.24% | -38.31% |
| Change in Net Operating Assets | 804.55% | 25.66% | -235.16% | 92.68% | -163.46% |
| Cash from Operations | -62.99% | -79.31% | -95.94% | 45.63% | -44.91% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 59.25% | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -4.98% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -116.36% | -103.51% | -8.88% | -- | -106.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -93.75% | -209.54% | -34.64% | 36.21% | -1,147.27% |